Peptide Law by State

Federal reclassification sets the floor; state pharmacy boards set the ceiling. The post-April-15 access landscape varies meaningfully by state. Coverage rolls out by state — full grid by July PCAC.

Multi-state action, Sept 18, 2026: twenty state attorneys general, led by Alabama's Steve Marshall, asked the Secretary of State and the National Security Council to treat Chinese-sourced ingredients in compounded GLP-1 drugs as a national-security matter. Every state page below carries the cross-reference; see the explainer and Alabama's tracker entry.

Permissive states

Standard compounding pharmacy access; minimal additional friction.

• Alabama — Permissive compounding environment with no additional state-level barriers beyond standard non-resident pharmacy registration. Standard telehealth-to-pharmacy workflow remains functional for peptide access following the April 15 FDA reclassification.
• Arizona — Permissive compounding environment with standard telehealth-to-pharmacy workflow. No additional state-level barriers beyond standard non-resident pharmacy registration following the April 15 FDA reclassification.
• Arkansas — No known state-level barriers. Standard compounding pharmacy access under valid prescription.
• Florida — Permissive-tier state and major national compounding hub. Nonresident pharmacies must hold a Florida Nonresident Pharmacy Permit (§ 465.0156) and Nonresident Sterile Compounding Permit (§ 465.0158); out-of-state telehealth providers can register under Fla. Stat. § 456.47.
• Georgia — Standard access. No significant state-level barriers.
• Idaho — Straightforward workflow. Standard telehealth-to-compounding path available.
• Indiana — Straightforward access. No known special restrictions on compounding pharmacy access.
• Kansas — Standard access. No significant state-level barriers reported.
• Kentucky — Standard compounding pharmacy workflow. Straightforward prescribing path.
• Louisiana — Standard access. No special restrictions beyond standard pharmacy licensing.
• Mississippi — Standard access. No significant restrictions on compounding pharmacy access.
• Missouri — Straightforward path. Standard compounding pharmacy access under valid prescription.
• Montana — Standard access due to lower population density. Telehealth-friendly.
• Nebraska — Standard access. No known special restrictions.
• Nevada — Standard access. Straightforward telehealth-to-compounding workflow.
• North Dakota — Standard access despite low population. Telehealth-friendly compounding access.
• Oklahoma — Standard access. No special restrictions reported.
• South Carolina — Standard access. No special restrictions reported.
• South Dakota — Standard access. Telehealth-friendly regulatory environment.
• Tennessee — Major compounding hub. Straightforward access.
• Texas — Texas runs one of the most workable compounding pharmacy regimes in the country and is a primary hub for national compounding operations.
• Utah — Standard access. Telehealth-friendly with multiple compounders active.
• West Virginia — Standard access. No special restrictions reported.
• Wyoming — Standard access. Low population but telehealth-friendly compounding access.

Moderate-tier states

One to two additional verification steps; expect 7–14 extra days on first order.

• Alaska — Board of pharmacy requires additional prescriber verification. Limited non-resident pharmacy access.
• Colorado — Moderate-tier compounding environment. Out-of-state pharmacies need Colorado nonresident registration (C.R.S. 12-280-133); a 2026 bill targeting compounded GLP-1s failed. Telehealth prescribing is permitted for non-controlled substances.
• Delaware — Moderate-tier state. Out-of-state pharmacies must hold a Delaware nonresident pharmacy license and a Delaware registered agent under 24 Del. C. 2535-2536; 503B outsourcing facilities must be licensed by the Board of Pharmacy, and telehealth prescribing requires a documented provider-patient relationship under Title 24, Chapter 60.
• Iowa — Moderate oversight. Board of pharmacy requires verification of out-of-state licenses.
• Maine — Moderate oversight. Some compounders may not hold Maine non-resident pharmacy licenses.
• Michigan — Moderate oversight. Out-of-state compounders must hold Michigan non-resident pharmacy license.
• Minnesota — Moderate barriers. Additional verification for telehealth prescribing across state lines.
• New Hampshire — Moderate oversight. Board requires verification for out-of-state prescriptions.
• New Mexico — Moderate oversight. Additional verification may be needed for telehealth prescribing.
• North Carolina — Moderate oversight. Board of pharmacy requires additional verification for compounders.
• Ohio — Moderate oversight. Non-resident pharmacy registration required for out-of-state compounders.
• Oregon — Moderate oversight. Board requires verification of compounder credentials.
• Pennsylvania — Moderate oversight. Some compounders may not serve PA without additional licensing.
• Rhode Island — Moderate barriers due to smaller market. Limited compounder presence.
• Virginia — Moderate oversight. Non-resident pharmacy registration process required.
• Washington — Moderate oversight. State board maintains additional verification requirements.
• Wisconsin — Moderate oversight. Board of pharmacy requires verification of compounder credentials.

Restrictive-tier states

Stricter non-resident pharmacy regimes, telehealth limits, or layered oversight.

• California — California maintains one of the strictest non-resident pharmacy licensing regimes in the country, materially limiting which compounders can ship in. No peptide-specific legislation has emerged in the 2026 session.
• Connecticut — Restrictive-tier state driven by enforcement. Out-of-state pharmacies must hold a Connecticut nonresident certificate (CGS 20-627); sterile compounders face USP 797/800/825 requirements under CGS 20-633b; the Attorney General has sued and settled against gray-market GLP-1 peptide sellers since May 2025.
• Hawaii — Limited compounding pharmacy access due to geography and smaller market. Extra lead time expected.
• Illinois — State board maintains stricter oversight. Additional verification requirements for out-of-state compounders.
• Maryland — Stricter state pharmacy board oversight. Non-resident compounder verification required.
• Massachusetts — Historically one of the stricter boards of pharmacy in the country. Additional verification expected.
• New Jersey — Stricter compounding pharmacy oversight. Non-resident pharmacy registration required.
• New York — New York maintains a restrictive non-resident pharmacy regime and additional state-level oversight on certain compounded categories.
• Vermont — Stricter oversight. Limited compounder presence. Expect additional verification.
• Washington D.C. — Stricter regulatory environment. Limited compounder access. Use caution.

How the tier classification works

• Permissive (24 states): Standard non-resident pharmacy registration; broad telehealth latitude; no peptide-specific layered oversight. AL, AZ, AR, FL, GA, ID, IN, KS, KY, LA, MS, MO, MT, NE, NV, ND, OK, SC, SD, TN, TX, UT, WV, WY.
• Moderate (17 states): 1-2 additional verification steps. AK, CO, DE, IA, ME, MI, MN, NH, NM, NC, OH, OR, PA, RI, VA, WA, WI.
• Restrictive (10 states + DC): Stricter regimes. CA, CT, HI, IL, MD, MA, NJ, NY, VT, DC.